Entero Healthcare Solutions Stock Price Today (NSE: ENTERO)
Fundamental Score
Entero Healthcare Solutions Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Entero Healthcare Solutions share price today is ₹1152.40, up +0.96% on NSE/BSE as of 19 June 2026. Entero Healthcare Solutions (ENTERO) is a Small-cap company in the Pharmacy Retail sector with a market capitalisation of ₹4.57K (Cr). The 52-week high for ENTERO share price is ₹1390.00 and the 52-week low is ₹944.00. At a P/E ratio of 41.31x, ENTERO is currently trading below its industry average P/E of 45.55x. The company has a Return on Equity (ROE) of 5.63% and a debt-to-equity ratio of 0.25.
Entero Healthcare Solutions Share Price Chart — NSE/BSE Historical Performance
Entero Healthcare Solutions share price chart: -5.18% return over the past month. 52-week high ₹1390.00, 52-week low ₹944.00.
Entero Healthcare Solutions — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1141.00 | ₹1159.00 | ₹1103.70 | ₹1152.40 | 2.26L (Cr) | |
| ₹1197.00 | ₹1209.90 | ₹1130.10 | ₹1141.40 | 1.22L (Cr) | |
| ₹1185.60 | ₹1204.10 | ₹1154.00 | ₹1195.80 | 2.20L (Cr) | |
| ₹1292.00 | ₹1298.80 | ₹1174.70 | ₹1185.40 | 4.94L (Cr) | |
| ₹1358.90 | ₹1358.90 | ₹1271.00 | ₹1283.50 | 5.80L (Cr) | |
| ₹1361.00 | ₹1390.00 | ₹1275.10 | ₹1349.40 | 2.53L (Cr) | |
| ₹1319.40 | ₹1374.00 | ₹1297.50 | ₹1354.40 | 2.82L (Cr) | |
| ₹1262.00 | ₹1318.60 | ₹1255.80 | ₹1299.90 | 3.92L (Cr) | |
| ₹1242.00 | ₹1260.60 | ₹1222.50 | ₹1254.70 | 1.86L (Cr) | |
| ₹1192.00 | ₹1268.00 | ₹1192.00 | ₹1240.10 | 1.95L (Cr) |
Entero Healthcare Solutions — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1197.00 | ₹1209.90 | ₹1103.70 | ₹1152.40 | -3.73% | |
| ₹1224.20 | ₹1390.00 | ₹1137.60 | ₹1195.80 | -2.32% | |
| ₹1264.90 | ₹1303.20 | ₹1145.00 | ₹1216.40 | -3.83% | |
| ₹987.00 | ₹1259.30 | ₹986.50 | ₹1247.80 | +26.42% | |
| ₹1148.80 | ₹1216.00 | ₹1008.00 | ₹1032.00 | -10.17% | |
| ₹1020.00 | ₹1247.50 | ₹1012.40 | ₹1104.90 | +8.32% | |
| ₹1060.00 | ₹1067.80 | ₹944.00 | ₹1026.60 | -3.15% | |
| ₹1105.40 | ₹1203.30 | ₹1022.00 | ₹1062.70 | -3.86% | |
| ₹1116.00 | ₹1149.00 | ₹1044.90 | ₹1105.40 | -0.95% | |
| ₹1193.80 | ₹1250.00 | ₹1057.10 | ₹1114.10 | -6.68% | |
| ₹1285.00 | ₹1313.90 | ₹1166.00 | ₹1182.00 | -8.02% | |
| ₹1148.90 | ₹1328.70 | ₹1130.50 | ₹1286.60 | +11.99% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Entero is a roll-up story in a fragmented market, but negative FCF and integration risks keep it on the watchlist.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search.
CORE STORY (THE REAL GAME)
Entero is a play on the organized healthcare supply chain, consolidating distribution in a fragmented market. It's about scale and efficiency, not drug discovery.
- Acquisition of Anand Chemiceutics completed
- Q3 2026 EBITDA growth of 36% YoY
- Focus shifting to integration and margin improvement
- Successful integration of acquisitions
- Further margin expansion
- Positive free cash flow generation
- Negative free cash flow
- Aggressive acquisition strategy
- Small-cap liquidity risk
FII decreased holdings by 2.53% and DII decreased holdings by 0.55%
India's pharmacy market is expected to grow at a CAGR of 10% from 2025 to 2030
Entero completed the acquisition of a 51.51% stake in Anand Chemiceutics for ₹2.1-2.3 billion on February 7, 2026.
No. Free Cash Flow 5Y: ₹-302.73 Cr
Focus on integrating acquisitions and improving margins over the next 3-6 months. Key is to see if they can generate positive free cash flow.
Primary Thesis Risk
Inability to generate free cash flow will kill the story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Entero Healthcare Solutions Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Entero Healthcare Solutions Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ENTERO across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Robust Profit Growth (33.78%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (20.78%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (30.44% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (151.54% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.25)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (52.42%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (5.63%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.71%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (2.33%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 41.31x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-25.34% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-302.73 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Entero Healthcare Solutions vs Pharmacy Retail Peers
Peer Comparison - Pharmacy Retail
Compare Entero Healthcare Solutions with 1 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Entero Healthcare SolutionsEntero Healthca...Selected✓ ENTERO • 544122 | 56.9/100 | ₹1152.40₹1152 | ₹4566.30₹4566.30 | 41.31Average 41.3 Average | 5.63%Poor 5.63% Poor | 8.71%Poor 8.71% Poor | 0.25Excellent 0.3 Excellent | 151.54%Excellent 151.54% Excellent | 30.44%Excellent 30.44% Excellent | 0.00% |
Medplus Health Services LtdMedplus Health ... MEDPLUS • 543427 | 30.9/100 | ₹881.85₹882 | ₹9713.43₹9713.43 | 49.79Average 49.8 Average | 8.80%Poor 8.80% Poor | 10.28%Average 10.28% Average | 0.65Good 0.7 Good | 131.42%Excellent 131.42% Excellent | 16.41%Excellent 16.41% Excellent | 0.00% |
Entero Healthcare Solutions PE Ratio History
Historical price-to-earnings ratio for ENTERO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹21.76 | ₹1026.60 | 47.2x |
| FY 2024 | ₹10.81 | ₹1424.15 | 131.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Entero Healthcare Solutions Quarterly Performance
Latest quarterly metrics for ENTERO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
20.78%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
33.78%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
30.44%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
151.54%
Compounded annual net profit growth over 5 years
Entero Healthcare Solutions Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ENTERO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Entero Healthcare Solutions Financial Statements
Annual income statement, balance sheet and cash flow for Entero Healthcare Solutions (ENTERO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Entero Healthcare Solutions
About ENTERO (Entero Healthcare Solutions)
Entero Healthcare Solutions is a pioneering force reshaping the pharmaceutical distribution landscape in India. The company operates as a critical intermediary, connecting pharmace...utical manufacturers with a vast network of retail pharmacies, hospitals, and clinics. Entero distinguishes itself by providing a comprehensive suite of services that go beyond simple logistics. They facilitate efficient and timely delivery of a wide array of products, from essential medicines and life-saving drugs to cutting-edge therapies and specialized medical supplies. The company’s technology-driven platform optimizes inventory management, demand forecasting, and order fulfillment, ensuring that healthcare providers have access to the products they need, when they need them. By streamlining the supply chain and reducing complexities, Entero enables pharmacies and healthcare institutions to focus on patient care. Entero’s expansive product portfolio caters to diverse medical needs, encompassing everything from established pharmaceutical brands to innovative biosimilars and nutraceuticals. The company meticulously selects its product range, ensuring quality, efficacy, and alignment with prevailing healthcare standards. In addition to pharmaceuticals, Entero provides a range of surgical products, consumables, and medical devices. This comprehensive offering makes Entero a one-stop-shop for healthcare providers, simplifying procurement and reducing the burden of managing multiple suppliers. The commitment to providing a diverse and high-quality product selection underscores Entero's dedication to supporting the entire healthcare ecosystem. Furthermore, Entero Healthcare Solutions is more than just a distribution company; it is a knowledge partner and solutions provider. They actively support their retail partners with valuable data insights, marketing programs, and training initiatives. By leveraging data analytics and market research, Entero equips pharmacies with the tools they need to make informed decisions about inventory management, pricing strategies, and product promotion. Their commitment to fostering mutually beneficial partnerships extends beyond simple transactions, building trust and enabling sustained growth for both Entero and its network of healthcare providers. This dedication to innovation and customer centricity positions Entero as a leader in the evolving pharmaceutical distribution market.
Company Details
Key Leadership
ENTERO Share Price: Frequently Asked Questions
What is the current share price of Entero Healthcare Solutions?
Entero Healthcare Solutions (ENTERO) trades at ₹1152.40 on NSE and BSE. Market cap ₹4.57K (Cr). Educational data only.
What is the P/E ratio of Entero Healthcare Solutions?
Entero Healthcare Solutions has a P/E of 41.31x vs industry average 45.55x.
What is the Bull Run score for Entero Healthcare Solutions?
Entero Healthcare Solutions has a Bull Run score of 56.9/100 based on 25+ financial parameters.
Does Entero Healthcare Solutions pay dividends?
Entero Healthcare Solutions has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Entero Healthcare Solutions?
Entero Healthcare Solutions has ROE of 5.63%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Entero Healthcare Solutions?
Entero Healthcare Solutions has debt-to-equity of 0.25.
Is Entero Healthcare Solutions a good investment?
Bull Run gives Entero Healthcare Solutions a score of 56.9/100. This is not investment advice — consult a SEBI-registered advisor.